miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A

Table 1 Demographic and clinical characteristics of melanoma patients from whom serum was collected

Case	Sex	Age (years)	Stage^a	LDH^b	Previous therapy	Targeted therapy^c	BR^d	TTF^e (days)
1	F	48	M1c	H	Fotemustine	DAB	PR	182
2	M	38	M1c	H	None	DAB	PR	144
3	F	64	M1b	N	None	DAB+TRAM	PR	234
4	M	71	M1c	N	None	DAB (5)➔DAB+TRAM	PR	1275
5	M	43	M1c	H	None	DAB	SD	148
6	M	47	M1c	H	Fotemustine	DAB	PR	147
7	F	82	M1c	H	Dacarbazine	VEMU	PD	-
8	M	81	M1c	H	None	VEMU	PD	-
9	M	57	M1c	H	None	VEMU	PR	223
10	M	60	M1b	N	None	DAB+TRAM	PR	1082
11	M	45	M1c	H	None	DAB+TRAM	PR	188
12	M	70	M1c	N	None	DAB+TRAM	PR	117
13	M	65	M1c	H	None	VEMU	PD	-
14	M	49	M1c	H	None	VEMU	PR	147
15	M	39	M1b	H	None	DAB	PD	-
16	M	81	M1c	H	None	VEMU	PD	-
17	F	46	M1c	H	None	DAB+TRAM	PR	244
18	M	56	M1c	N	Nivolumab	DAB+TRAM	PR	504
19	M	57	M1c	H	None	DAB+TRAM	PR	172
20	M	35	M1c	H	None	DAB+TRAM	PR	180
21	F	78	M1a	N	None	DAB+TRAM	SD	83
22	M	66	M1b	N	None	DAB+TRAM	CR	1387
23	M	61	M1c	N	None	DAB+TRAM	PR	333
24	F	67	M1c	H	None	VEMU+COBI	PR	270
25	M	47	M1a	N	None	DAB+TRAM	PD	-
26	F	49	M1c	N	None	DAB+TRAM	PR	476

^aStage at first serum collection (i.e. T0).
^bN, normal; H, >1.5 upper limit of normal values
^cDAB, dabrafenib. TRAM, trametinib. VEMU, vemurafenib, COBI, cobimetinib. In parenthesis, months of monotherapy before trametinib addiction.
^dBest response according to RECIST 1.1 criteria: PR, partial response; SD, stable disease; PD, progressive disease.
^eTTF, time to treatment failure.

ISSN: 1756-9966